Theramex Says Currently Considering CMA's Decision, In Particular Whether And How Best To Address Competition Concerns Regarding Deal With Viatris; " Co Remains Committed To Offering Women Choice To Make Empowered Decisions About HRT At Competitive Prices For NHS"; Phase 1 Of CMA's Decision To Have No Impact On Co's Ability To Supply Existing HRT Products In UK
Theramex表示目前正在考虑CMA的决定，特别是是否以及如何最好地解决与Viatris交易有关的竞争问题；“公司仍然致力于为女性提供选择权，让她们以具有竞争力的价格为NHS做出有关HRT的决定”；CMA决定对公司在英国供应现有HRT产品的能力不产生影响的第一阶段